P50 amplitude reduction: A nicotinic receptor-mediated deficit in first-degree relatives of schizophrenia patients

Psychopharmacology

Volumn 221, Issue 1, 2012, Pages 39-52

  Turetsky, Bruce I ^a   Dent, Gersham ^b   Jaeger, Judith ^b   Zukin, Stephen R ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Amplitude; Gating; Genetic vulnerability; Nicotine; P50; Schizophrenia; Smoking

Indexed keywords

COTININE; NICOTINE; NICOTINIC RECEPTOR; PLACEBO;

ABSORPTION; ABSTINENCE; ADULT; ARTICLE; AUDITORY STIMULATION; BLOOD LEVEL; CONTROLLED STUDY; EXPOSURE; FAMILY STUDY; FEMALE; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN EXPERIMENT; MALE; NICOTINE ABSORPTION; P50 AUDITORY SENSORY GATING; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; SERUM NICOTINE; SMOKING;

ADOLESCENT; ADULT; EVOKED POTENTIALS, AUDITORY; FAMILY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NICOTINE; RECEPTORS, NICOTINIC; SCHIZOPHRENIA; SENSORY GATING; SMOKING; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84859646401     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2544-5     Document Type: Article

References (55)

1. Adler LE, Pachtman E, Franks RD, Pecevich M, Waldo MC, Freedman R (1982) Neurophysiological evidence for a defect in neuronal mechanisms involved in sensory gating in schizophrenia. Biol Psychiatry 17:639-654 (Pubitemid 12090209)
2. Adler LE, Gerhardt GA, Franks R, Baker N, Nagamoto H, Drebing C, Freedman R (1990) Sensory physiology and catecholamines in schizophrenia and mania. Psychiatry Res 31:297-309 (Pubitemid 20102378)
3. Adler LE, Hoffer LJ, Griffith J, Waldo MC, Freedman R (1992) Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenia. Biol Psychiatry 32:607-616
4. Adler LE, Hoffer LJ, Wiser A, Freedman R (1993) Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry 150:1856-1861 (Pubitemid 23356580)
5. Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT et al (2004) Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry 161:1822-1828 (Pubitemid 39314676)
6. Barr RS, Culhane MA, Jubelt LE, Mufti RS, Dyer MA, Weiss AP et al (2008) The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology 33:480-490
7. Benowitz NL, Zevin S, Jacob P III (1998) Suppression of nicotine intake during ad libitum cigarette smoking by high-dose transdermal nicotine. J Pharmacol Exp Ther 287:958-962 (Pubitemid 29131607)
8. Boutros NN, Overall J, Zouridakis G (1991) Test-retest reliability of the P50 mid-latency auditory evoked response. Psychiatry Res 39:181-192
9. Boutros NN, Brockhaus-Dumke A, Gjini K, Vedeniapin A, Elfakhani M, Burroughs S, Keshavan M (2009) Sensory-gating deficit of the N100 mid-latency auditory evoked potential in medicated schizophrenia patients. Schizophr Res 113:339-346
10. Chang WP, Arfken CL, Sangal MP, Boutros NN (2011) Probing the relative contribution of the first and second responses to sensory gating indices: a meta-analysis. Psychophysiology 48:980-992
11. Clementz BA, Blumenfeld LD (2001) Multichannel electroencephalographic assessment of auditory evoked response suppression in schizophrenia. Exp Brain Res 139:377-390 (Pubitemid 32703944)
12. Clementz BA, Geyer MA, Braff DL (1998) Poor P50 suppression among schizophrenia patients and their first-degree biological relatives. Am J Psychiatry 155:1691-1694 (Pubitemid 28547492)
13. Crawford HJ, McClain-Furmanski D, Castagnoli N Jr, Castagnoli K (2002) Enhancement of auditory sensory gating and stimulus-bound gamma band (40 Hz) oscillations in heavy tobacco smokers. Neursci Lett 317:151-155 (Pubitemid 34033734)
14. Cullum CM, Harris JG, Waldo MC, Smernoff E, Madison A, Nagamoto HT, Griffith J et al (1993) Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr Res 10:131-141 (Pubitemid 23273366)
15. Dautzenberg B, NidesM, Kienzler JL, Callens A (2007) Pharmacokinetics, safety and efficacy from randomized controlled trials of 1 and 2 mg nicotine bitartrate lozenges (Nicotinell). BMC Clin Pharmacol 7:11
16. De Luca V, Wong AH, Muller DJ, Wong GW, Tyndale RF, Kennedy JL (2004) Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology 29:1522-1526 (Pubitemid 38982245)
17. Fisher JL, Pidoplichko VI, Dani JA (1998) Nicotine modifies the activity of ventral tegmental area dopaminergic neurons and hippocampal GABAergic neurons. J Physiol Paris 92:209-213 (Pubitemid 29050936)
18. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD (1983) Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 18:537-551 (Pubitemid 13135325)
19. Freedman R, Adler LE, Gerhardt GA, Waldo M, Baker N, Rose GM et al (1987) Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull 13:669-678 (Pubitemid 18037660)
20. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci 94:587-592 (Pubitemid 27053677)
21. Fuerst DR, Gallinat J, Boutros NN (2007) Range of sensory gating values and test-retest reliability in normal subjects. Psychophysiology 44:620-626 (Pubitemid 46905321)
22. Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149:1189-1194
23. Gottesman II, Gould TD (2003) The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160:636-645 (Pubitemid 41079594)
24. Hasselblad V (1966) Estimation of parameters for a mixture of normal distributions. Technometrics 8:431-444
25. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991) The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 86:1119-1127
26. Jansen BH, Hegde A, Boutros NN (2004) Contribution of different EEG frequencies to auditory evoked potential abnormalities in schizophrenia. Clin Neurophysiol 115:975-978
27. Jin Y, Potkin SG, Patterson JV, Sandman CA, Hetrick WP, Bunney WE Jr (1997) Effects of P50 temporal variability on sensory gating in schizophrenia. Psychiatry Res 70:71-81 (Pubitemid 27245156)
28. Knott V, Millar A, Fisher D, Albert P (2010) Effects of nicotine on the amplitude and gating of the auditory P50 and its influence by dopamine D2 receptor gene polymorphism. Neuroscience 166:145-156
29. Lamberti JS, Schwarzkopf SB, Boutros N, Crilly JF, Martin R (1993) Within-session changes in sensory gating assessed by P50 evoked potentials in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 17:781-791 (Pubitemid 23280953)
30. Leonard S, Adams C, Breese CR, Adler LE, Bickfors P, Byerley Wet al (1996) Nicotinic receptor function in schizophrenia research. Schizophr Bull 22:431-445 (Pubitemid 26295346)
31. Light GA, Malaspina D, Geyer MA, Luber BM, Coleman EA, Sackeim HA, Braff DL (1999) Amphetamine disrupts P50 suppression in normal subjects. Biol Psychiatry 46:990-996 (Pubitemid 29452990)
32. Light GA, Geyer MA, Clementz BA, Cadenhead KS, Braff DL (2000) Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications. Am J Psychiatry 157:767-771 (Pubitemid 30249656)
33. Manickavasagom A, Pereira EFR, Almeida LEF, Randall WR, Albuquerque EX (2000) Nicotine at concentrations found in cigarette smokers activates and desensitizes nicotinic acetylcholine receptors in CA1 interneurons of rat hippocampus. Neuropsychopharmacology 39:2726-2739
34. Marshall DL, Redfern PH, Wonnacott S (2002) Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem 68:1511-1519 (Pubitemid 27133058)
35. McEvoy JP, Freudenreich O, Wilson WH (1999) Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 46:125-129 (Pubitemid 29296825)
36. Metzger KL, Maxwell CR, Liang Y, Siegel SJ (2007) Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry 61:23-30 (Pubitemid 44855732)
37. Moxon KA, Gerhart GA, Adler LE (2003) Dopaminergic modulation of the P50 auditory- evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia. Biol Cybern 88:265-275
38. Myles-Worsley M (2002) P50 sensory gating in multiplex schizophrenia families from a Pacific island isolate. Am J Psychiatry 159:663-667
39. Nagamoto HT, Adler LE, Hea RA, Griffith JM, McRae KA, Freedman R (1996) Gating of auditory P50 in schizophrenics: unique effects of clozapine. Biol Psychiatry 40:181-188 (Pubitemid 26349110)
40. NIMH Genetics Initiative (1992) Family Interview for Genetic Studies (FIGS). National Institute of Mental Health, Rockville
41. Noble E, Gottschalk L, Gallon J, Ritchie TW (1997) D2 dopamine receptor polymorphism and brain regional metabolism. Am J Med Genet 74:162-166 (Pubitemid 27187645)
42. Nurnberger JI Jr, Belhar MC, Kaufman CA, York-Cooler C, Simpson SG, Harkavy-Friedman J (1994) Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry 51:849-859 (Pubitemid 24985906)
43. Patterson JV, Hetrick WP, Boutros NN, Jin Y, Sandman C, Stern H, Potkin S, Bunney WE Jr (2008) P50 sensory gating ratios in schizophrenics and controls: A review and data analysis. Psychiatry Res 158:226-247
44. Potter D, Summerfelt A, Gold J, Buchanan RW (2006) Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 32:692-700 (Pubitemid 44412856)
45. Radek RJ, Miner HM, Bratcher NA, Decker MW, Gopalakrishnan M, Bitner RS (2006) Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating. Psychopharmacology (Berl) 187:47-55 (Pubitemid 43876915)
46. Rudnick N, Koehler C, Picciotto M, Siegel S (2009) Role of beta2- containing nicotinic acetylcholine receptors in auditory eventrelated potential. Psychopharmacology 202:749-751
47. Sacco KA, Termine A, Seyal A, Dudas MM, Vessicchio JC, Krishnan- Sarin S et al (2005) Effects of cigarette smoking on spatial working memory and attentional deficits in schizophrenia. Arch Gen Psychiatry 62:649-659 (Pubitemid 40973440)
48. Sánchez-Morla EM, Santos JL, Aparicio A, García- Jiménez MA, Villanueva C, Martínez-Vizcaíno V, Arango C (2009) Antipsychotic effects on auditory sensory gating in schizophrenia patients. Eur Neuropsychopharmacol 19:905-909
49. Siegel C, Waldo M, Mizner G, Adler L, Freedman R (1984) Deficits in sensory gating in schizophrenic patients and their relatives. Arch Gen Psychiatry 41:607-612
50. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR (2007) Neurophysiologial endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 33:69-94 (Pubitemid 46026260)
51. Waldo MC, Cawthra E, Adler LE, Dubester S, Staunton M, Nagamoto H et al (1994) Auditory sensory gating, hippocampal volume, and catecholamine metabolism in schizophrenics and their siblings. Schizophr Res 12:93-106 (Pubitemid 24135500)
52. Waldo M, Myles-Worsley M, Madison A, Byerley W, Freedman R (1995) Sensory gating deficits in parents of schizophrenics. Am J Med Genet 60:506-511 (Pubitemid 26002117)
53. Wan L, Friedman BH, Boutros NN, Crawford HJ (2008) P50 sensory gating and attentional performance. Int J Psychophysiol 67:91-100 (Pubitemid 351163416)
54. White PM, Yee CM (2006) P50 sensitivity to physical and psychological state influences. Psychophysiology 43:320-328 (Pubitemid 43927350)
55. Yee CM, Nuechterlein KH, Morris SE, White PM (1998) P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. J Abnorm Psychol 107:691-698 (Pubitemid 28527584)